STAGE IVB PROSTATE CANCER AJCC V8

This phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visib…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, ivuxolimab, or radiation) in 173 people with advanced cancers that have not responded to standard therapies. The goal is to find tolerable doses and see i…

This phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…

This study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to the bones. Olaparib blocks a protein that cancer cells use to repair themselves, while radium-223 delivers radiation directly to bone tumors. Th…

This phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. …

This early-phase trial tests a new type of immunotherapy called PSCA-CAR T cells in 14 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment involves taking a patient's own immune cells, engineer…

This phase 2 trial tests a fixed-dose combination of niraparib and abiraterone acetate plus prednisone in 8 men with metastatic castration-resistant prostate cancer that has a SPOP gene mutation. The drugs work by blocking cancer cell repair and reducing inflammation. The main go…

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 c…

This study tests whether adding rucaparib to standard enzalutamide helps men with metastatic prostate cancer that has stopped responding to hormone therapy. About 61 men will receive either the combination or enzalutamide alone. The goal is to see if the combo slows cancer growth…

This study tests a combination of three drugs (apalutamide, abiraterone, and prednisone) given after chemotherapy for men with advanced prostate cancer that has spread and hasn't been treated before. The goal is to see if this approach can lower PSA levels more effectively and al…

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in adults with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the disease. About 65 particip…

This study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…

This study is for men with a type of prostate cancer that no longer responds to hormone therapy and has spread to the bones. Researchers are using a special scan called PSMA PET to see if it can identify which patients will get the most benefit from a radiation therapy called Ra-…

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men whose prostate cancer has spread but who have not yet received hormone therapy. The goal is to see how long patients can stay on treatment and to measure cancer progression and side…

This study tests whether adding the drug relugolix to standard radiation therapy can delay cancer growth in men with prostate cancer that has spread to a few other spots in the body. Relugolix lowers testosterone, which some cancer cells need to grow. About 194 men will receive e…

This study tests a special PET scan (68Ga-PSMA-11) to see if it can find and monitor prostate cancer more accurately than standard scans. About 141 men with prostate cancer that has come back or spread will get the scan. The goal is to help doctors choose the best treatment.

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…